Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging

Participants in the IARC/NCI workshop on Primary Endpoints for Prophylactic HPV Vaccine Trials

doi:10.1016/S1470-2045(15)70075-6

Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging

Participants in the IARC/NCI workshop on Primary Endpoints for Prophylactic HPV Vaccine Trials

Research output: Contribution to journal › Article › Scientific › peer-review

38 Citations (Scopus)

Original language	English
Pages (from-to)	e226-e233
Journal	LANCET ONCOLOGY
Volume	16
Issue number	5
DOIs	https://doi.org/10.1016/S1470-2045(15)70075-6
Publication status	Published - 2015
Publication type	A1 Journal article-refereed

Publication forum classification

Publication forum level 2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(15)70075-6

Cite this

@article{a5df77b2ea874d3590b7f4f7cfeac437,

title = "Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging",

author = "{Participants in the IARC/NCI workshop on Primary Endpoints for Prophylactic HPV Vaccine Trials} and Lowy, {Douglas R} and Rolando Herrero and Allan Hildesheim and Matti Lehtinen",

year = "2015",

doi = "10.1016/S1470-2045(15)70075-6",

language = "English",

volume = "16",

pages = "e226--e233",

journal = "LANCET ONCOLOGY",

issn = "1470-2045",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging

AU - Participants in the IARC/NCI workshop on Primary Endpoints for Prophylactic HPV Vaccine Trials

AU - Lowy, Douglas R

AU - Herrero, Rolando

AU - Hildesheim, Allan

AU - Lehtinen, Matti

PY - 2015

Y1 - 2015

U2 - 10.1016/S1470-2045(15)70075-6

DO - 10.1016/S1470-2045(15)70075-6

M3 - Article

SN - 1470-2045

VL - 16

SP - e226-e233

JO - LANCET ONCOLOGY

JF - LANCET ONCOLOGY

IS - 5

ER -